Loading…
Loading…
See exactly how HRTS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HRTS and 80,000+ other tickers.
The Tema Heart & Health ETF (HRTS) is designed to strategically invest in companies poised to benefit from cutting-edge developments within the biotechnology and broader healthcare industries. Its investment mandate specifically targets firms focused on advancing treatments and therapies for cardiovascular health, metabolic disorders, and weight management.
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors.
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced that the firm has surpassed $2 billion in assets under management. The milestone comes less than eight months after surpassing $1 billion, and less than three years after listing its first ETF with under $5 million in seed capital. Tema's recent growth has been led by three 2026 highlights: Institutional Adoption: More than 90% of Tema's AUM has been sourc.